Novartis | NOVN - Sales Revenues


Novartis reported $14.41B in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Alcon AG USD 2.69B 10M Mar/2026
Almirall EUR 602.71M 55.09M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Autolus Therapeutics Ltd USD 26.22M 1.93M Mar/2026
Bayer EUR 10.87B 2.54B Jun/2026
Biogen USD 2.74B 490M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Fresenius EUR 5.95B 210M Jun/2026
Fresenius Medical Care EUR 4.86B 250M Jun/2026
Genmab DKK 1.16B 259M Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
GRIFOLS EUR 1.87B 170M Jun/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
J&J USD 25.31B 1.21B Jun/2026
Lakefront Biotherapeutics EUR 6.5M 894.32M Mar/2026
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.13B 120M Mar/2026
Merck USD 16.6B 310M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Novartis USD 13.11B 750M Mar/2026
Novo Nordisk DKK 78.49B 18.33B Jun/2026
Orion EUR 521.6M 103.9M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Philips EUR 4.36B 450M Jun/2026
Recordati EUR 681.35M 32.07M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
UCB EUR 4.25B 764M Dec/2025